• Matthew H Anstey, Muhamad S Aljeaidi, Robert Palmer, Angela Jacques, Bhaumik Mevavala, Edward Litton, and Bradley Wibrow.
• Sir Charles Gairdner Hospital, Australia; Medical School, The University of Western Australia, Perth, WA, Australia; Curtin University, Australia. Electronic address: matthew.anstey@health.wa.gov.au.
• J Crit Care. 2023 Dec 1; 78: 154369154369.

PurposeTo determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock.MethodsDouble-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemia was clinically excluded. Patients received either intravenous 1.5 g sodium ascorbate in 100 ml normal saline every 6 h for 5 days, or placebo (100 ml normal saline). The primary outcome was duration of vasopressor usage in hours. Secondary outcomes were ICU and hospital length of stay, and 28-day, ICU and hospital mortality.ResultsOf the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37-54 h] and 55 h [95% CI, 33-66 h]) in the vitamin C and placebo groups (p = 0.057). ICU and hospital length of stay, mortality outcomes were similar between groups.ConclusionsIn this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors.Trial RegistrationProspective registration - trial number ACTRN12617001392358.Copyright © 2023 Elsevier Inc. All rights reserved.

17 keywords...

hide…